Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=41,054 Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)
Hypertension
Primary: Blood Pressure Remeasurement — 245; 829; 1813 participants — p=<0.001
Phase 2 N=109 Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington Disease
Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants
Phase 3 N=35 Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
Hypertension
Primary: Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). — -2.86 Millimeters of Mercury (mm Hg)
N/A N=116 Pediatric Guideline Adherence and Outcomes- Argentina
TBI (Traumatic Brain Injury)
Primary: First 3-day Cumulative Intensive Care Unit (ICU) Traumatic Brain Injury (TBI) Guideline Adherence Rate, Overall — 81.7; 81.0; 83.7; 84.4 mean percentage of guideline…
Phase 2 N=134 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington Disease
Primary: Number of Patients With at Least One Adverse Event — 119 Participants
Phase 4 N=6 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2
Early Phase 1 N=11 Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis
Hemiparesis
Primary: Adverse Events/Safety Assessment. — 0; 0; 0; 0 Participants
Phase 2 N=128 Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia
Congenital Hyperinsulinism (CHI) · Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Primary: Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism — 34; 10; 4; 52 cases
Phase 3 N=58 Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
Hunter Syndrome
Primary: Change From Baseline in the Differential Ability Scales, Second Edition (DAS-II) General Conceptual Ability (GCA) Standard Score at Week 52 — -7.4; -4.4 Score on a scale…
Phase 3 N=63 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
Phase 2 N=21 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease
Sanfilippo Syndrome
Primary: Number of Participants With Overall Response Using Bayley Scales of Infant Development Assessment Third Edition (BSID-III) — 0; 2; 1 participants — p=0.4615
N/A N=183 Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Human Immunodeficiency Virus · Immune Reconstitution Inflammatory Syndrome
Primary: All-cause Mortality — 21; 18 participants
N/A N=150 Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
Sickle Cell Anemia
Primary: Change in Qualitative Spleen Function From Randomized Control Trial Baseline Measurement - Compared Between Children Randomized to Hydroxyurea vs Placebo — 26; 28; 32…
Phase 2 N=58 Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Sickle Cell Anemia
Primary: Number of Patients Enrolled. — 58 Participants
N/A N=17 High Frequency Oscillation in Pediatric Epilepsy Surgery
Pediatric Epilepsy · Epilepsy Surgery · High Frequency Oscillation
Primary: Post-operative Seizure-free Rate — 4; 5; 4; 4 Participants
Phase 2 N=106 Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Congenital Hyperinsulinism · Hyperinsulinism · Persistent Hyperinsulinemic Hypoglycemia of Infancy
Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
N/A N=22 Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
Hypoplastic Left Heart Syndrome
Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days
Phase 3 N=114 PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
Chronic Hepatitis C
Primary: Sustained Viral Response (SVR) — 29; 12 participants
Phase 3 N=702 Pediatric Open-Label Extension Study
Schizophrenia · Autism · Bipolar Depression
Primary: Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) — 214; 106; 252; 572 Participants
Phase 3 N=327 Pediatric Schizophrenia Efficacy and Safety Study
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6. — 94.5; 94.0; 92.8; -18.6 units on a scale — p=0.0003
Phase 2 N=47 Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
Acute Leukaemia · Chronic Disease · Leukemia
Primary: Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments — 16; 18; 10 participants
N/A N=14 Measuring Head Control Change With 2D Video Analysis After Utilization of Headpod in Children With Poor Head Control
To Determine Efficacy of the Headpod · Cerebral Palsy
Primary: Change in Head Holding Active Time From Baseline to 6 Months — 83.63 Seconds
N/A N=10 Pediatric Teleneuromodulation
Cerebral Palsy (CP)
Primary: Status/Safety Assessment — 4; 7; 20; 12 number of sessions symptom reported
Phase 2 N=50 H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Diffuse Intrinsic Pontine Glioma · Glioma · Diffuse Midline Glioma, H3 K27M-Mutant
Primary: Percentage of Participants With Adverse Events (AE) Related to Treatment — 5.26; 0; 0; 21.0 percentage of participants
Phase 3 N=23 Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
Urea Cycle Disorders
Primary: Adverse Events — 0; 6 participants
N/A N=42 Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Huntington's Disease
Primary: Quantitative Electroencephalography Absolute Delta Power. — 43.45; 10.11 microvolts squared — p=<0.0000001
Phase 2 N=15 An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
Hunter Syndrome
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 4; 10; 5 Participants
Phase 2 N=30 Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
Pediatric Cancer
Primary: Percentage of Pediatric Patients Age 3-7 Who Require Daily General Anesthesia for All Treatments — 88; 12 percentage of participants